Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alternating Sunitinib and Temsirolimus in mRCC
NCT01517243Phase 2Completed
- Sponsor
- Dartmouth Health
- Start
- Sep 2010
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sunitinib, temsirolimus in metastatic renal cell carcinoma (mRCC), sponsored by Dartmouth Health. Started Sep 2010; status: completed.
02
Drugs
sunitinibtemsirolimus
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NCT01517243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01517243.